All Investigations
OSINT · Publicly Available Sources INVESTIGATION ORACLE

The Chemical Restraint of America's Foster Children

February 28, 2026 OPUS · Claude Opus Project Milk Carton SSI PI License #5337

The Chemical Restraint of America's Foster Children

Across the United States, approximately 391,000 children in foster care are caught in a pharmaceutical pipeline that prescribes them psychotropic medications at rates 5 to 9 times higher than non-foster children - often without informed consent, judicial authorization, or independent medical revi...

OPUS INVESTIGATION: The Chemical Restraint of America's Foster Children

How States Sedate Vulnerable Youth at Industrial Scale While Pharmaceutical Companies Profit Billions from Medicaid

Investigation Date: February 28, 2026 Classification: OPUS Deep Investigation Investigator: ARIA Intelligence System - Project Milk Carton Status: ACTIVE - Patterns of Systemic Abuse Identified


EXECUTIVE SUMMARY

Across the United States, approximately 391,000 children in foster care are caught in a pharmaceutical pipeline that prescribes them psychotropic medications at rates 5 to 9 times higher than non-foster children - often without informed consent, judicial authorization, or independent medical review. Children as young as 2 years old are prescribed antipsychotics, mood stabilizers, and sedatives that carry FDA Black Box warnings for suicidal ideation in minors.

This investigation documents a nationwide crisis at the intersection of child welfare, pharmaceutical profit, and government failure - where the most vulnerable children in America are being chemically restrained rather than therapeutically treated.

Key Findings: - 35 percent of foster youth are prescribed at least one psychotropic medication vs. 8 percent of non-foster Medicaid peers - a 6.8x disparity after controlling for diagnoses - Foster youth are prescribed an average of 2.9 drug classes simultaneously vs. 1.4 for non-foster youth - 48 percent of children in group homes are on psychotropic medications, vs. 12-14 percent in family foster care - Hundreds of pre-teens in Texas and Washington were found on 4+ concurrent psychotropic medications - Johnson and Johnson paid 2.2 billion dollars in federal fines and 800 million dollars in settlements for illegally marketing Risperdal to children and foster youth - Medicaid spends at least 6 billion dollars annually on psychiatric drugs - nearly 30 percent of its entire drug budget - Seven states confirmed they have no child welfare policies specific to psychotropic medication oversight - The HHS Office of Inspector General found that 1 in 3 foster children on psychotropic meds received no treatment planning or medication monitoring


SECTION 1: THE SCOPE

1.1 Prescribing Rates: The Disparity Gap

Metric Foster Youth Non-Foster Medicaid Youth Ratio
Any psychotropic prescription 35 percent 8 percent 4.4x
Odds of prescription (adjusted) 6.8x higher Baseline 6.8x
Mean drug classes prescribed 2.9 1.4 2.1x
Group home medication rate 48 percent N/A -
Family foster care rate 12-14 percent N/A -

Nationwide, 20 to 40 percent of foster care youth are prescribed psychotropic medications, compared to 4 to 10 percent of general Medicaid-enrolled children. This represents approximately 80,000 to 160,000 children in state custody receiving psychiatric drugs at any given time.

1.2 Polypharmacy: The Cocktail Problem

  • Between 58 and 84 percent of foster children on behavioral services receive more than one psychotropic drug simultaneously
  • Hundreds of foster children in Texas and Washington are prescribed 4+ concurrent medications
  • The GAO found that no evidence supports the use of 5 or more concurrent psychotropic drugs in adults or children
  • Nearly 100,000 children in the system receive at least two psychotropics simultaneously

1.3 The Youngest Victims

  • Children as young as 2 years old are being prescribed antipsychotic medications in foster care
  • A Maine lawsuit documented foster children as young as 5 receiving powerful psychotropic drugs
  • Ke-onte, an 11-year-old in Texas foster care, was prescribed at least 12 different psychotropic medications

SECTION 2: THE DRUGS

2.1 Most Commonly Prescribed

Drug (Brand) Class FDA Approved for Children? Key Risks
Risperdal (risperidone) Antipsychotic Limited Gynecomastia, metabolic syndrome, diabetes
Abilify (aripiprazole) Antipsychotic Limited FDA Black Box: suicidal ideation in children
Seroquel (quetiapine) Antipsychotic Limited Metabolic syndrome, weight gain, sedation
Adderall/Vyvanse Stimulant ADHD (6+) Cardiovascular, appetite suppression
Zoloft/Prozac SSRI Limited FDA Black Box: suicidal ideation in children
Depakote (valproate) Mood Stabilizer Epilepsy only Liver failure, pancreatitis

2.2 Off-Label Prescribing

  • Foster children with ADHD were prescribed antipsychotics at 3x the rate of other children
  • Risperdal was the most commonly prescribed antipsychotic to foster youth with ADHD
  • Researchers found the trend appears linked to socio-economic status, not good medical standards

2.3 Documented Harms

Named Victims: - Gabriel Myers, age 7 - died by suicide in 2009 while prescribed two psychotropic medications in Florida - Jimmy Vaughn - taking as many as seven drugs simultaneously as a child in foster care - DeAngelo Cortijo - in over a dozen foster homes by age 14, prescribed cocktail of antipsychotics - Ke-onte (Texas) - 11 years old, prescribed 12 different psychotropic medications - A 16-year-old in Maryland - overdosed twice on his medications


SECTION 3: THE MONEY

3.1 Medicaid Pipeline

  • Medicaid spends at least 6 billion dollars annually on psychiatric drugs - nearly 30 percent of drug budget
  • Medicaid spending on psychotropic drugs has more than doubled since 1999
  • In high-prescribing cases, Medicaid costs grew 1,334 percent over ten years

3.2 Title IV-E Funding

National total FY2023: 9.5 billion dollars in Title IV-E spending - Texas alone: 174-189 million dollars annually in Title IV-E awards - States expended 1.2 billion dollars of Medicaid funding through child welfare agencies in SFY2022

3.3 The Risperdal Scandal

  • 1999-2005: FDA repeatedly warned J and J about promoting Risperdal for use in children
  • November 2013: J and J paid 2.2 billion dollar federal fine for illegal promotion
  • September 2021: Settled 9,000 individual claims for 800 million dollars
  • Texas settlement: 158 million dollars for marketing fraud
  • One jury verdict: 8 billion dollars (later reduced to 6.8 million)
  • Total J and J Risperdal liability: Over 3 billion dollars

3.4 Pharmacy Benefit Managers

  • Six major PBMs control 95 percent of U.S. prescriptions
  • PBMs generate revenue through spread pricing - charging Medicaid more than they pay pharmacies
  • FTC found PBMs continuously profited by overcharging patients
  • 24 states passed 33 bills in 2024 to regulate PBM practices

3.5 Group Homes

  • Group homes: 48 percent psychotropic medication rate vs. 12-14 percent in family foster care
  • More than half of California group home foster children sedated with chemical restraints

SECTION 4: THE OVERSIGHT FAILURE

4.1 HHS OIG Findings

  • 1 in 3 children received no treatment planning or medication monitoring
  • State requirements did not incorporate professional practice guidelines
  • Medications not accurately documented in child welfare information systems
  • California OIG Audit (2023): Did not comply with federal documentation requirements

4.2 GAO Reports: A Decade of Warnings Ignored

Report Year Key Finding
GAO-12-201 2011 States need improved oversight
GAO-12-270T 2012 No evidence supports 5+ drug cocktails
GAO-14-362 2014 Additional guidance needed for MCOs
GAO-14-651T 2014 HHS could provide additional guidance
GAO-17-129 2017 HHS taken steps but gaps persist

4.3 States Without Any Oversight

Seven states with NO psychotropic-specific policies: 1. Massachusetts 2. North Dakota 3. Arkansas 4. West Virginia 5. Kansas 6. Alabama 7. Kentucky

Connecticut model (best practice): In-house consent unit with nurses and psychiatrist What most states do: A caseworker checks a box


SECTION 5: THE LAWSUITS

Case State Year Status
Bryan C. v. Lambrew Maine 2024 SETTLED
M.B. v. Tidball Missouri 2025 SETTLED
ACLU/DRM v. Maryland DHS Maryland 2023 PENDING

Maine Settlement (2024) - The Blueprint

Three reforms: medical records, informed consent, psychiatric clinical review. Affects 500 children.

Missouri Settlement (2025) - The Precedent

First federal class-action focused solely on psychotropic medication in foster care.

Maryland Litigation (2023-Present)

34 percent of Maryland foster children on psychotropics. Named plaintiff overdosed twice.

Children Rights Inc. (EIN: 13-3801864)

Revenue (2023): 6.5 million | Assets: 14.9 million | Employees: ~50 Key Funders: Global Impact (300K), Fidelity Charitable (62.5K), Goldman Sachs Foundation (35K)


SECTION 6: RACIAL DISPARITIES

  • 2.17-fold white-to-Black disparity in psychotropic use (16.5 percent vs. 7.6 percent)
  • When Black children ARE prescribed, more likely to receive antipsychotics
  • Black children: 23 percent of foster youth vs. 14 percent of general child population
  • California 10-year analysis: disparities narrowed 38-59 percent

SECTION 7: CHILD WELFARE STATE COMPARISON (PMC CivicOps Data)

State Child Victims (2023) Rate per 1,000 Fatalities
Texas 54,476 7.2 187
California 47,824 5.7 150
New York 46,431 11.7 123
Florida 22,842 5.2 75
Maryland 6,074 4.5 83
Missouri 4,419 3.2 61
Maine 3,741 15.0 7

SECTION 8: THE CHEMICAL RESTRAINT QUESTION

Are foster children being medicated for their benefit, or for the convenience of the system?

Evidence points toward the latter: - Group homes (48 percent medicated) vs. family foster care (12-14 percent) - Medications used to subdue rather than treat children (Lakota People Law Project) - Evidence-based trauma therapies rarely provided alongside medication - Former foster youth report: All I did was sleep

AACAP recommends psychotherapy BEFORE medication, trauma-informed care as first-line response.


SECTION 9: RECOMMENDATIONS

For Congress

  • Mandate independent psychiatric review before any foster child psychotropic prescription
  • Require informed consent from medically qualified representative
  • Mandate real-time Medicaid reporting on foster psychotropic prescriptions
  • Create federal ombudsman for foster care medication oversight
  • Require PBM spread pricing transparency

For HHS/ACF

  • Issue binding regulations, not voluntary guidance
  • Create national dashboard tracking prescribing rates
  • Condition Title IV-E funding on compliance
  • Mandate evidence-based trauma therapy before medication

For State Legislatures

  • Adopt Connecticut model with medical consent units
  • Ban psychotropic prescribing for children under 6 without board review
  • Require judicial authorization for polypharmacy (3+ concurrent drugs)
  • Fund trauma-informed therapy alternatives

SECTION 10: SOURCES

Government: HHS OIG (2018, 2023), GAO-12-201, GAO-17-129, Texas HHS (2024) Research: PubMed 37204275, PMC10808658, PMC4041742, PMC3373221, PMC4061230 Journalism: The Imprint, NPR, KFF Health News, Health Affairs Legal: Bryan C. v. Lambrew (ME), M.B. v. Tidball (MO), ACLU v. MD DHS Database: PMC CivicOps (340M+ records), USASpending, CourtListener


CONCLUSION

The chemical restraint of America foster children is not a failure of information - it is a failure of political will. Every relevant fact in this report has been known to federal and state officials for over a decade.

And still, in 2026, approximately 100,000 of America most vulnerable children wake up every morning and take psychiatric medications that were prescribed not to heal their trauma, but to make them easier to manage.

The question is not whether America knows about this crisis. The question is whether America cares enough to stop it.


This investigation was produced by ARIA, the intelligence system of Project Milk Carton, a 501(c)(3) organization dedicated to child welfare transparency and missing children awareness.

Project Milk Carton | EIN: 33-1323547 | projectmilkcarton.org


SCRIBE NOTES: Formatted for dual-anchor video article conversion. Recommended segments: (1) Opening with prescribing statistics, (2) Named victim stories, (3) The Risperdal scandal, (4) State oversight failures map, (5) The lawsuit movement, (6) Call to action.